Literature DB >> 24809242

Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.

Chris J Edgar1, Thomas Blaettler2, Dragana Bugarski-Kirola2, Stephanie Le Scouiller3, George M Garibaldi2, Stephen R Marder4.   

Abstract

The PANSS is a valid instrument assessing schizophrenia symptom severity. Analyses have identified a five-factor solution. The negative symptom factor (NSFS) is robust, having been replicated in multiple analyses. The score has superior content validity versus the negative subscale. Aspects of validity in patients with predominant negative symptoms have yet to be established. The present data are from a Phase IIb study of add-on bitopertin therapy in schizophrenia outpatients with prominent negative or disorganized thought symptoms treated with antipsychotics. Analyses were conducted to evaluate reliability, validity and sensitivity to change. Test-retest screening to baseline was high (ICC=0.93). This was maintained in-study, for patients with no change in CGI negative symptom severity (CGI-S-N). Internal consistency at baseline was adequate (α=0.71) and increased at later assessments. Pearson correlation at baseline showed a good association between NSFS and CGI-S-N (0.63), but not overall CGI-S (0.31). Association with PSP at baseline was moderate (-0.39) and for change at Week eight good (-0.65). NSFS responders (≥20% improvement) at Week eight showed a significant improvement in function. The analyses demonstrated reliability, validity and ability to detect change of the NSFS, in schizophrenia patients with prominent negative or disorganized thought symptoms.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Clinical trials; NSFS; Negative symptom factor; Negative symptoms; Outcome assessment; PANSS; Psychiatric rating scales

Mesh:

Substances:

Year:  2014        PMID: 24809242     DOI: 10.1016/j.psychres.2014.04.009

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

1.  Cognitive Impairment and Diminished Neural Responses Constitute a Biomarker Signature of Negative Symptoms in Psychosis.

Authors:  Matthew E Hudgens-Haney; Brett A Clementz; Elena I Ivleva; Matcheri S Keshavan; Godfrey D Pearlson; Elliot S Gershon; Sarah K Keedy; John A Sweeney; Florence Gaudoux; Pierre Bunouf; Benoit Canolle; Françoise Tonner; Silvia Gatti-McArthur; Carol A Tamminga
Journal:  Schizophr Bull       Date:  2020-02-11       Impact factor: 9.306

2.  Individualized covariance profile of cortical morphology for auditory hallucinations in first-episode psychosis.

Authors:  Je-Yeon Yun; Sung Nyun Kim; Tae Young Lee; Myong-Wuk Chon; Jun Soo Kwon
Journal:  Hum Brain Mapp       Date:  2015-12-17       Impact factor: 5.038

3.  Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia.

Authors:  Antoni Sicras-Mainar; Jorge Maurino; Elena Ruiz-Beato; Ruth Navarro-Artieda
Journal:  Neuropsychiatr Dis Treat       Date:  2014-12-30       Impact factor: 2.570

4.  A Two-Factor Model Better Explains Heterogeneity in Negative Symptoms: Evidence from the Positive and Negative Syndrome Scale.

Authors:  Seon-Kyeong Jang; Hye-Im Choi; Soohyun Park; Eunju Jaekal; Ga-Young Lee; Young Il Cho; Kee-Hong Choi
Journal:  Front Psychol       Date:  2016-05-12

Review 5.  Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy.

Authors:  Leslie Citrome
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-05       Impact factor: 2.570

6.  The component structure of the scales for the assessment of positive and negative symptoms in first-episode psychosis and its dependence on variations in analytic methods.

Authors:  Marc S Tibber; James B Kirkbride; Eileen M Joyce; Stanley Mutsatsa; Isobel Harrison; Thomas R E Barnes; Vyv Huddy
Journal:  Psychiatry Res       Date:  2018-10-30       Impact factor: 3.222

7.  EPA guidance on assessment of negative symptoms in schizophrenia.

Authors:  S Galderisi; A Mucci; S Dollfus; M Nordentoft; P Falkai; S Kaiser; G M Giordano; A Vandevelde; M Ø Nielsen; L B Glenthøj; M Sabé; P Pezzella; I Bitter; W Gaebel
Journal:  Eur Psychiatry       Date:  2021-02-18       Impact factor: 5.361

8.  Neural Correlates of Schizophrenia Negative Symptoms: Distinct Subtypes Impact Dissociable Brain Circuits.

Authors:  Joseph J Shaffer; Michael J Peterson; Mary Agnes McMahon; Joshua Bizzell; Vince Calhoun; Theo G M van Erp; Judith M Ford; John Lauriello; Kelvin O Lim; Dara S Manoach; Sarah C McEwen; Daniel H Mathalon; Daniel O'Leary; Steven G Potkin; Adrian Preda; Jessica Turner; Jim Voyvodic; Cynthia G Wible; Aysenil Belger
Journal:  Mol Neuropsychiatry       Date:  2015-10-17

9.  Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia.

Authors:  Seth C Hopkins; Ajay Ogirala; Antony Loebel; Kenneth S Koblan
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.